

Hijacking Low-Density Lipoprotein Receptor For Extracellular Protein Degradation And Degradation-Drug Conjugates

Tech ID: 34633 / UC Case 2025-121-0

INVENTION NOVELTY

VALUE PROPOSITION

TECHNOLOGY DESCRIPTION

UCSF researchers have developed a new bifunctional antibody for modulation of membrane proteins, offering a dual approach of targeted degradation and potent cell killing by using low-density lipoprotein receptor targeting chimeras with a cytotoxic payload. This new innovation offers several compelling benefits in the biopharmaceutical and oncology sectors to enhance efficacy in targeting and killing cancer cells, combine protein degradation with cytotoxic payload delivery, targeting membrane-bound or secreted proteins, and reduces dose-limiting toxicities.

APPLICATION

LOOKING FOR PARTNERS

STAGE OF DEVELOPMENT

RELATED MATERIALS

DATA AVAILABILITY

PATENT STATUS

Patent Pending

CONTACT

Darya (Dasha) Bubman
Darya.Bubman@ucsf.edu
tel: 415-237-1585.



OTHER INFORMATION

KEYWORDS

Low-density lipoprotein, low-density lipoprotein receptor (LDLR), LDLR-targeting chimeras (LIPTACs), degrader-drug conjugates (DDCs), lysosomal delivery, UCSF innovation

CATEGORIZED AS

- ▶ **Biotechnology**
- ▶ Health
- ▶ **Materials & Chemicals**
- ▶ Biological
- ▶ **Research Tools**
- ▶ Antibodies

RELATED CASES

2025-121-0

ADDRESS

UCSF

Innovation Ventures

600 16th St, Genentech Hall, S-272,
San Francisco, CA 94158

CONTACT

Tel:

innovation@ucsf.edu

<https://innovation.ucsf.edu>

Fax:

CONNECT

 Follow  Connect

© 2026, The Regents of the University of
California

[Terms of use](#) [Privacy Notice](#)